William S Oetting1, David P Schladt2, Casey R Dorr2,3, Baolin Wu4, Weihua Guan4, Rory P Remmel5, David Iklé6, Roslyn B Mannon7, Arthur J Matas8, Ajay K Israni3,4,9, Pamala A Jacobson1. 1. Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN. 2. Hennepin Healthcare Research Institute, Minneapolis, MN. 3. Department of Medicine, Hennepin Healthcare, Minneapolis, MN. 4. Department of Biostatistics, University of Minnesota, Minneapolis, MN. 5. Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN. 6. Rho, Chapel Hill, NC. 7. Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL. 8. Department of Surgery, University of Minnesota, Minneapolis, MN. 9. Department of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: Identifying kidney allograft recipients who are predisposed to acute rejection (AR) could allow for optimization of clinical treatment to avoid rejection and prolong graft survival. It has been hypothesized that a part of this predisposition is caused by the inheritance of specific genetic variants. There are many publications reporting a statistically significant association between a genetic variant, usually in the form of a single-nucleotide polymorphism (SNP), and AR. However, there are additional publications reporting a lack of this association when a different cohort of recipients is analyzed for the same single-nucleotide polymorphism. METHODS: In this report, we attempted to validate 75 common genetic variants, which have been previously reported to be associated with AR, using a large kidney allograft recipient cohort of 2390 European Americans and 482 African Americans. RESULTS: Of those variants tested, only 1 variant, rs2910164, which alters the expression of the microRNA MIR146A, was found to exhibit a significant association within the African American cohort. Suggestive variants were found in the genes CTLA and TLR4. CONCLUSIONS: Our results show that most variants previously reported to be associated with AR were not validated in our cohort. This shows the importance of validation when reporting the associations with complex clinical outcomes such as AR. Additional work will need to be done to understand the role of MIR146A in the risk of AR in kidney allograft recipients.
BACKGROUND: Identifying kidney allograft recipients who are predisposed to acute rejection (AR) could allow for optimization of clinical treatment to avoid rejection and prolong graft survival. It has been hypothesized that a part of this predisposition is caused by the inheritance of specific genetic variants. There are many publications reporting a statistically significant association between a genetic variant, usually in the form of a single-nucleotide polymorphism (SNP), and AR. However, there are additional publications reporting a lack of this association when a different cohort of recipients is analyzed for the same single-nucleotide polymorphism. METHODS: In this report, we attempted to validate 75 common genetic variants, which have been previously reported to be associated with AR, using a large kidney allograft recipient cohort of 2390 European Americans and 482 African Americans. RESULTS: Of those variants tested, only 1 variant, rs2910164, which alters the expression of the microRNA MIR146A, was found to exhibit a significant association within the African American cohort. Suggestive variants were found in the genes CTLA and TLR4. CONCLUSIONS: Our results show that most variants previously reported to be associated with AR were not validated in our cohort. This shows the importance of validation when reporting the associations with complex clinical outcomes such as AR. Additional work will need to be done to understand the role of MIR146A in the risk of AR in kidney allograft recipients.
Authors: William S Oetting; David P Schladt; Robert E Leduc; Pamala A Jacobson; Weihua Guan; Arthur J Matas; Ajay Israni Journal: Transpl Int Date: 2011-09-29 Impact factor: 3.782
Authors: S E Marshall; A J McLaren; E F McKinney; T G Bird; N A Haldar; M Bunce; P J Morris; K I Welsh Journal: Transplantation Date: 2001-02-15 Impact factor: 4.939
Authors: D Sankaran; A Asderakis; S Ashraf; I S Roberts; C D Short; P A Dyer; P J Sinnott; I V Hutchinson Journal: Kidney Int Date: 1999-07 Impact factor: 10.612
Authors: Bernd Krüger; Carsten A Böger; Aiman Obed; Stefan Farkas; Ute Hoffmann; Bernhard Banas; Michael Fischereder; Bernhard K Krämer Journal: Clin Transplant Date: 2007 May-Jun Impact factor: 2.863
Authors: Maria P Hernandez-Fuentes; Christopher Franklin; Irene Rebollo-Mesa; Jennifer Mollon; Florence Delaney; Esperanza Perucha; Caragh Stapleton; Richard Borrows; Catherine Byrne; Gianpiero Cavalleri; Brendan Clarke; Menna Clatworthy; John Feehally; Susan Fuggle; Sarah A Gagliano; Sian Griffin; Abdul Hammad; Robert Higgins; Alan Jardine; Mary Keogan; Timothy Leach; Iain MacPhee; Patrick B Mark; James Marsh; Peter Maxwell; William McKane; Adam McLean; Charles Newstead; Titus Augustine; Paul Phelan; Steve Powis; Peter Rowe; Neil Sheerin; Ellen Solomon; Henry Stephens; Raj Thuraisingham; Richard Trembath; Peter Topham; Robert Vaughan; Steven H Sacks; Peter Conlon; Gerhard Opelz; Nicole Soranzo; Michael E Weale; Graham M Lord Journal: Am J Transplant Date: 2018-02-01 Impact factor: 8.086
Authors: Yanni Li; Lianne M Nieuwenhuis; Brendan J Keating; Eleonora A M Festen; Vincent E de Meijer Journal: Transplantation Date: 2021-12-28 Impact factor: 5.385